Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Petzer

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|August 31, 2017
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1Sonja Burgstaller, Reinhard Stauder, Thomas Kuehr, et al.
Cancers|September 28, 2021
The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and BeyondIrene Strassl, Martin Schreder, Normann Steiner, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2016
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14)Michael A Fridrik, Ulrich Jaeger, Andreas Petzer, et al.
Wiener Klinische Wochenschrift|November 20, 2020
Austrian recommendations for the management of essential thrombocythemiaVeronika Buxhofer-Ausch, Sonja Heibl, Thamer Sliwa, et al.
Wiener Klinische Wochenschrift|December 15, 2016
Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statementThamer Sliwa, Christine Beham-Schmid, Sonja Burgstaller, et al.
Wiener Klinische Wochenschrift|January 1, 2009
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platformPeter Valent, Thomas Lion, Dominik Wolf, et al.
Wiener Klinische Wochenschrift|July 21, 2018
Austrian recommendations for the management of polycythemia veraSonja Burgstaller, Veronika Buxhofer-Ausch, Thamer Sliwa, et al.
Therapeutic Advances in Medical Oncology|October 25, 2021
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
Scientific Reports|September 18, 2023
Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatmentBernhard Doleschal, Hossein Taghizadeh, Gerald Webersinke, et al.
Wiener Klinische Wochenschrift|July 26, 2018
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy managementMaria-Theresa Krauth, Sonja Burgstaller, Veronika Buxhofer-Ausch, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|August 31, 2017
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1Sonja Burgstaller, Reinhard Stauder, Thomas Kuehr, et al.
Cancers|September 28, 2021
The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and BeyondIrene Strassl, Martin Schreder, Normann Steiner, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2016
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14)Michael A Fridrik, Ulrich Jaeger, Andreas Petzer, et al.
Wiener Klinische Wochenschrift|November 20, 2020
Austrian recommendations for the management of essential thrombocythemiaVeronika Buxhofer-Ausch, Sonja Heibl, Thamer Sliwa, et al.
Wiener Klinische Wochenschrift|December 15, 2016
Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statementThamer Sliwa, Christine Beham-Schmid, Sonja Burgstaller, et al.
Wiener Klinische Wochenschrift|January 1, 2009
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platformPeter Valent, Thomas Lion, Dominik Wolf, et al.
Wiener Klinische Wochenschrift|July 21, 2018
Austrian recommendations for the management of polycythemia veraSonja Burgstaller, Veronika Buxhofer-Ausch, Thamer Sliwa, et al.
Therapeutic Advances in Medical Oncology|October 25, 2021
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
Scientific Reports|September 18, 2023
Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatmentBernhard Doleschal, Hossein Taghizadeh, Gerald Webersinke, et al.
Wiener Klinische Wochenschrift|July 26, 2018
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy managementMaria-Theresa Krauth, Sonja Burgstaller, Veronika Buxhofer-Ausch, et al.
Pageof 7